𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A safety study of oral xanthohumol administration and its influence on fertility in Sprague Dawley rats

✍ Scribed by Ragna Hussong; Norbert Frank; Jutta Knauft; Carina Ittrich; Robert Owen; Hans Becker; Clarissa Gerhäuser

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
148 KB
Volume
49
Category
Article
ISSN
1613-4125

No coin nor oath required. For personal study only.

✦ Synopsis

Xanthohumol (XN) is a prenylated chalcone, which has been shown to possess a broad range of potential cancer preventive and additional biological activities. In the present study, we have determined the subchronic 4-wk toxicity of XN and monitored its influence on fertility and development of offspring in two fertility studies. Four-week-old female Sprague Dawley (SD) rats were treated with 0.5% XN in the diet or with 1,000 mg XN/kg body weight (b.w.) per day by gavage for 28 days. No remarkable treatment-related changes in general appearance and b.w. occurred during the study. After autopsy, liver, kidney, lung, heart, stomach, and spleen were examined macroscopically and histopathologically. Relative liver weights of animals in both treatment groups were significantly reduced by 30--40% in comparison with the control group, indicating weak hepatotoxicity. Also, mammary glands of treated rats appeared less developed compared to the controls. Consequently, we investigated the influence of XN on rat reproduction. In two fertility studies, XN (100 mg/kg b.w. per day), given either for 4 wk prior to or during mating, gestation, and nursing, did not cause any adverse effects on female reproduction and the development of offspring. Noteworthy, treatment of male rats prior to mating significantly (p=0.027) increased the sex ratio of male to female offspring. Overall, lifelong treatment at a daily dose of 100 mg/kg b.w. in a two-generation study did not affect the development of SD rats.

📜 SIMILAR VOLUMES

A safety study of a B-class CpG ODN in S
A safety study of a B-class CpG ODN in Sprague–Dawley rats
✍ Li Liu; Lianzhong Shen; Xiaomeng Liu; Yongli Yu; Yinzeng Li; Liying Wang; Chunya 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 312 KB 👁 1 views

## ABSTRACT Oligodeoxynucleotides containing CpG motifs (CpG ODNs) are potent immune activators and are being tested as anti‐tumor, antimicrobial agents and as adjuvants in vaccines. Little has been reported, however, about the systematic and comprehensive safety evaluation on repeated CpG ODN admi

Lack of effects on fertility and develop
Lack of effects on fertility and developmental toxicity of a quadrivalent HPV vaccine in Sprague-Dawley rats
✍ L. David Wise; Jayanthi J. Wolf; Catherine V. Kaplanski; Cindy J. Pauley; Brian 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 307 KB 👁 2 views

## Abstract Human papillomavirus (HPV) infection is one of the most common sexually transmitted diseases, with approximately half of the HPV‐infected people being adolescents and young adults. A recently developed quadrivalent HPV vaccine, GARDASIL^®^, has been shown to be highly effective in the p

Kinetic study of a 2-hydroxypropyl-β-cyc
Kinetic study of a 2-hydroxypropyl-β-cyclodextrin-based formulation of all-trans-retinoic acid in Sprague-Dawley rats after oral or intravenous administration
✍ Hai-Shu Lin; Sui Yung Chan; Kerwin Siew Yang Low; Mei Leng Shoon; Paul C. Ho 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 191 KB 👁 1 views

all-trans-Retinoic acid (ATRA, vitamin A acid, or tretinoin) is a potent chemotherapeutic agent for the treatment of acute promyelocytic leukemia (APL). Its poor aqueous solubility not only affects its oral absorption but also prevents it from forming an aqueous parenteral formulation. Recently, we

Pharmacokinetic study of all-trans-retin
Pharmacokinetic study of all-trans-retinoyl-β-D-glucuronide in Sprague–Dawley rats after single and multiple intravenous administration(s)
✍ Hai-Shu Lin; Arun B. Barua; James A. Olson; Kerwin Siew Yang Low; Sui Yung Chan; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB

All-trans-retinoyl-b-D-glucuronide (RAG) is an endogenous active metabolite of all-trans-retinoic acid (ATRA). In the present study, the pharmacokinetics of RAG was examined after the administration of a single intravenous does (5, 10, or 15 mmol/kg) and of multiple daily intravenous doses (5 mmol/k